EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments

Cecilie Bo Hansen iD, Kristina Dvoncova, Laura Pérez-Alós, Kamille Fogh, Johannes Roth Madsen iD, Caroline Hartwell Garred, Ida Jarlhelt, Pernille Brok Nielsen, Steffan Svejgaard Petersen, Charlotte Gandsø Fjordager, Klara Tølbøll Lauritsen, Linda Hilsted and 4 more

Journal of Internal Medicine · 2023

DOI: 10.1111/joim.13637 ↗

At a glance

Journal article in Journal of Internal Medicine, 2023. Written by Cecilie Bo Hansen and 15 co-authors. Institution: Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmar…. Major MEDLINE topics: COVID-19. Cited 6 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Carlsbergfondet, Novo Nordisk Fonden.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Factors influencing SARS‐CoV‐2 antibody dynamics, transmission, waning and long COVID‐19 symptomatology are still not fully understood.

Methods

In the Danish section of the Novo Nordisk Group, we performed a prospective seroepidemiological study during the first and second waves of the COVID‐19 pandemic. All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6‐month follow‐up (December 2020–January 2021), and 12‐month follow‐up (August 2021) sampling. In total, 18,614 accepted and provided at least one blood sample and completed a questionnaire regarding socioeconomic background, health status, previous SARS‐CoV‐2 infection, and persistent symptoms. Total antibody and specific IgM, IgG and IgA levels against recombinant receptor binding domain were tested.

Results

At baseline, the SARS‐CoV‐2‐antibody seroprevalence was 3.9%. At 6‐month follow‐up, the seroprevalence was 9.1%, while at 12‐month follow‐up, the seroprevalence was 94.4% (after the vaccine roll‐out). Male sex and younger age (18–40 years) were significant risk factors for seropositivity. From baseline to the 6‐month sampling, we observed a substantial waning of IgM, IgG and IgA levels ( p < 0.001), regardless of age, sex and initial antibody level. An increased antibody level was found in individuals infected prior to vaccination compared to vaccinated infection naïves ( p < 0.0001). Approximately a third of the seropositive individuals reported one or more persistent COVID‐19 symptoms, with anosmia and/or ageusia (17.5%) and fatigue (15.3%) being the most prevalent.

Conclusion

The study provides a comprehensive insight into SARS‐CoV‐2 antibody seroprevalence following infection and vaccination, waning, persistent COVID‐19 symptomatology and risk factors for seropositivity in large working environments.

Subjects

MeSH terms (MEDLINE)

COVID-19HumansMaleAdolescentYoung AdultAdultPandemicsPost-Acute COVID-19 SyndromeProspective StudiesSARS-CoV-2Seroepidemiologic StudiesWorking ConditionsAntibodies, ViralRisk FactorsImmunoglobulin AImmunoglobulin GImmunoglobulin M

Author keywords

SARS-CoV-2antibodyinfectionlong COVIDtransmissionwaningworking environment

Substances

Antibodies, ViralImmunoglobulin AImmunoglobulin GImmunoglobulin M

Authors and institutions

  • Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Emergency Medicine and Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark.
  • Novo Nordisk A/S, Måløv, Denmark.
  • Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • The National Biobank, Statens Serum Institut, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID profiles: Cecilie Bo Hansen, Johannes Roth Madsen, Kasper Karmark Iversen, Peter Garred

Funding

  • Carlsbergfondet
  • Novo Nordisk Fonden

Cite

APA

Hansen, C. B., Dvoncova, K., Pérez-Alós, L., Fogh, K., Madsen, J. R., Garred, C. H., Jarlhelt, I., Nielsen, P. B., Petersen, S. S., Fjordager, C. G., Lauritsen, K. T., Hilsted, L., Boding, L., Iversen, K. K., Hyveled, L., & Garred, P. (2023). SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments. Journal of Internal Medicine. https://doi.org/10.1111/joim.13637

Vancouver

Hansen CB, Dvoncova K, Pérez-Alós L, Fogh K, Madsen JR, Garred CH, et al. SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments. Journal of Internal Medicine. 2023. doi:10.1111/joim.13637

BibTeX
@article{Hansen2023,
  author = {Hansen, Cecilie Bo and Dvoncova, Kristina and Pérez-Alós, Laura and Fogh, Kamille and Madsen, Johannes Roth and Garred, Caroline Hartwell and Jarlhelt, Ida and Nielsen, Pernille Brok and Petersen, Steffan Svejgaard and Fjordager, Charlotte Gandsø and Lauritsen, Klara Tølbøll and Hilsted, Linda and Boding, Lasse and Iversen, Kasper Karmark and Hyveled, Liselotte and Garred, Peter},
  title = {SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments},
  journal = {Journal of Internal Medicine},
  year = {2023},
  doi = {10.1111/joim.13637}
}
Start for free →